nodes	percent_of_prediction	percent_of_DWPC	metapath
Ergotamine—ABCB1—adrenal gland cancer	0.818	1	CbGaD
Ergotamine—SLC6A2—sympathetic nervous system—adrenal gland cancer	0.00815	0.21	CbGeAlD
Ergotamine—HTR2A—sympathetic nervous system—adrenal gland cancer	0.0049	0.126	CbGeAlD
Ergotamine—HTR2A—vein—adrenal gland cancer	0.00458	0.118	CbGeAlD
Ergotamine—CYP1A2—urine—adrenal gland cancer	0.00343	0.0885	CbGeAlD
Ergotamine—HTR2A—urine—adrenal gland cancer	0.00268	0.0692	CbGeAlD
Ergotamine—Dihydroergotamine—ABCB1—adrenal gland cancer	0.00253	0.415	CrCbGaD
Ergotamine—CYP3A4—urine—adrenal gland cancer	0.00248	0.064	CbGeAlD
Ergotamine—Ergonovine—ABCB1—adrenal gland cancer	0.00231	0.379	CrCbGaD
Ergotamine—HTR2B—adrenal cortex—adrenal gland cancer	0.00133	0.0343	CbGeAlD
Ergotamine—Bromocriptine—ABCB1—adrenal gland cancer	0.00126	0.206	CrCbGaD
Ergotamine—SLC6A2—gonad—adrenal gland cancer	0.00098	0.0253	CbGeAlD
Ergotamine—HTR2B—adrenal gland—adrenal gland cancer	0.000961	0.0248	CbGeAlD
Ergotamine—DRD2—pituitary gland—adrenal gland cancer	0.000871	0.0225	CbGeAlD
Ergotamine—HTR1A—adrenal gland—adrenal gland cancer	0.000861	0.0222	CbGeAlD
Ergotamine—SLC6A2—adrenal gland—adrenal gland cancer	0.000854	0.022	CbGeAlD
Ergotamine—ADRA1A—adrenal gland—adrenal gland cancer	0.000794	0.0205	CbGeAlD
Ergotamine—ADRA2A—gonad—adrenal gland cancer	0.000693	0.0179	CbGeAlD
Ergotamine—ADRA2A—cardiac atrium—adrenal gland cancer	0.000692	0.0178	CbGeAlD
Ergotamine—ADRA2A—pituitary gland—adrenal gland cancer	0.000676	0.0174	CbGeAlD
Ergotamine—ADRA2A—adrenal gland—adrenal gland cancer	0.000604	0.0156	CbGeAlD
Ergotamine—HTR2A—gonad—adrenal gland cancer	0.000589	0.0152	CbGeAlD
Ergotamine—HTR2A—pituitary gland—adrenal gland cancer	0.000575	0.0148	CbGeAlD
Ergotamine—HTR2A—adrenal gland—adrenal gland cancer	0.000513	0.0132	CbGeAlD
Ergotamine—ABCB1—adrenal cortex—adrenal gland cancer	0.000466	0.012	CbGeAlD
Ergotamine—ABCB1—gonad—adrenal gland cancer	0.000386	0.00995	CbGeAlD
Ergotamine—ABCB1—pituitary gland—adrenal gland cancer	0.000377	0.0097	CbGeAlD
Ergotamine—ABCB1—adrenal gland—adrenal gland cancer	0.000336	0.00867	CbGeAlD
Ergotamine—DRD2—Signaling Pathways—SPRY2—adrenal gland cancer	6.28e-05	0.000459	CbGpPWpGaD
Ergotamine—HTR2B—GPCR downstream signaling—POMC—adrenal gland cancer	6.28e-05	0.000459	CbGpPWpGaD
Ergotamine—ADRA1B—Signaling Pathways—MEN1—adrenal gland cancer	6.24e-05	0.000456	CbGpPWpGaD
Ergotamine—ADRA2A—GPCR downstream signaling—CDC42—adrenal gland cancer	6.22e-05	0.000454	CbGpPWpGaD
Ergotamine—HTR1F—Signaling Pathways—BAD—adrenal gland cancer	6.21e-05	0.000454	CbGpPWpGaD
Ergotamine—HTR2A—Signaling by GPCR—CDC42—adrenal gland cancer	6.21e-05	0.000453	CbGpPWpGaD
Ergotamine—HTR1D—Signaling by GPCR—POMC—adrenal gland cancer	6.2e-05	0.000453	CbGpPWpGaD
Ergotamine—HTR2A—Signaling Pathways—SPRY2—adrenal gland cancer	6.18e-05	0.000452	CbGpPWpGaD
Ergotamine—HTR2B—Signaling Pathways—PRKACA—adrenal gland cancer	6.17e-05	0.000451	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—GNRH1—adrenal gland cancer	6.15e-05	0.000449	CbGpPWpGaD
Ergotamine—DRD2—Signaling Pathways—TSHR—adrenal gland cancer	6.12e-05	0.000447	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling by GPCR—CDC42—adrenal gland cancer	6.08e-05	0.000444	CbGpPWpGaD
Ergotamine—HTR1B—Signaling by GPCR—POMC—adrenal gland cancer	6.07e-05	0.000443	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling Pathways—SPRY2—adrenal gland cancer	6.05e-05	0.000442	CbGpPWpGaD
Ergotamine—DRD2—Signaling by GPCR—GNAS—adrenal gland cancer	6.03e-05	0.00044	CbGpPWpGaD
Ergotamine—HTR2A—Signaling Pathways—TSHR—adrenal gland cancer	6.02e-05	0.00044	CbGpPWpGaD
Ergotamine—ABCB1—Metabolism—SDHD—adrenal gland cancer	5.98e-05	0.000437	CbGpPWpGaD
Ergotamine—ABCB1—Metabolism—RRM1—adrenal gland cancer	5.98e-05	0.000437	CbGpPWpGaD
Ergotamine—ADRA2A—GPCR downstream signaling—GNAS—adrenal gland cancer	5.94e-05	0.000434	CbGpPWpGaD
Ergotamine—HTR2A—Signaling by GPCR—GNAS—adrenal gland cancer	5.93e-05	0.000433	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling Pathways—TSHR—adrenal gland cancer	5.9e-05	0.000431	CbGpPWpGaD
Ergotamine—HTR1E—Signaling Pathways—BAD—adrenal gland cancer	5.86e-05	0.000428	CbGpPWpGaD
Ergotamine—ADRA1D—GPCR downstream signaling—POMC—adrenal gland cancer	5.84e-05	0.000427	CbGpPWpGaD
Ergotamine—CYP1A2—Metabolism of lipids and lipoproteins—PRKACA—adrenal gland cancer	5.83e-05	0.000426	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling by GPCR—GNAS—adrenal gland cancer	5.81e-05	0.000424	CbGpPWpGaD
Ergotamine—DRD2—Signaling Pathways—MEN1—adrenal gland cancer	5.76e-05	0.00042	CbGpPWpGaD
Ergotamine—ADRA1D—Signaling Pathways—PRKACA—adrenal gland cancer	5.74e-05	0.000419	CbGpPWpGaD
Ergotamine—HTR1F—Signaling Pathways—POMC—adrenal gland cancer	5.72e-05	0.000418	CbGpPWpGaD
Ergotamine—CYP3A4—Metabolism—SDHB—adrenal gland cancer	5.72e-05	0.000418	CbGpPWpGaD
Ergotamine—HTR2B—Signaling by GPCR—POMC—adrenal gland cancer	5.7e-05	0.000416	CbGpPWpGaD
Ergotamine—HTR1D—Signaling Pathways—CDC42—adrenal gland cancer	5.69e-05	0.000416	CbGpPWpGaD
Ergotamine—HTR2A—Signaling Pathways—MEN1—adrenal gland cancer	5.66e-05	0.000414	CbGpPWpGaD
Ergotamine—HTR1F—Signaling Pathways—BRAF—adrenal gland cancer	5.65e-05	0.000413	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling by GPCR—CDC42—adrenal gland cancer	5.65e-05	0.000413	CbGpPWpGaD
Ergotamine—ABCB1—Transmembrane transport of small molecules—GNAS—adrenal gland cancer	5.63e-05	0.000411	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—SPRY2—adrenal gland cancer	5.62e-05	0.000411	CbGpPWpGaD
Ergotamine—HTR1B—Signaling Pathways—CDC42—adrenal gland cancer	5.57e-05	0.000407	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling Pathways—MEN1—adrenal gland cancer	5.55e-05	0.000405	CbGpPWpGaD
Ergotamine—HTR1D—Signaling Pathways—IGF2—adrenal gland cancer	5.48e-05	0.000401	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—TSHR—adrenal gland cancer	5.48e-05	0.0004	CbGpPWpGaD
Ergotamine—HTR1F—Signaling by GPCR—EGFR—adrenal gland cancer	5.48e-05	0.0004	CbGpPWpGaD
Ergotamine—HTR1D—Signaling Pathways—GNAS—adrenal gland cancer	5.44e-05	0.000397	CbGpPWpGaD
Ergotamine—HTR1E—Signaling Pathways—POMC—adrenal gland cancer	5.4e-05	0.000395	CbGpPWpGaD
Ergotamine—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—adrenal gland cancer	5.4e-05	0.000394	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling by GPCR—GNAS—adrenal gland cancer	5.4e-05	0.000394	CbGpPWpGaD
Ergotamine—HTR1B—Signaling Pathways—IGF2—adrenal gland cancer	5.37e-05	0.000392	CbGpPWpGaD
Ergotamine—HTR1E—Signaling Pathways—BRAF—adrenal gland cancer	5.33e-05	0.00039	CbGpPWpGaD
Ergotamine—HTR1B—Signaling Pathways—GNAS—adrenal gland cancer	5.32e-05	0.000389	CbGpPWpGaD
Ergotamine—ADRA1D—Signaling by GPCR—POMC—adrenal gland cancer	5.3e-05	0.000387	CbGpPWpGaD
Ergotamine—HTR1D—Signaling Pathways—IGF1R—adrenal gland cancer	5.3e-05	0.000387	CbGpPWpGaD
Ergotamine—ADRA2B—GPCR downstream signaling—POMC—adrenal gland cancer	5.27e-05	0.000385	CbGpPWpGaD
Ergotamine—HTR2B—Signaling Pathways—CDC42—adrenal gland cancer	5.23e-05	0.000382	CbGpPWpGaD
Ergotamine—HTR1B—Signaling Pathways—IGF1R—adrenal gland cancer	5.19e-05	0.000379	CbGpPWpGaD
Ergotamine—ADRA2B—Signaling Pathways—PRKACA—adrenal gland cancer	5.18e-05	0.000379	CbGpPWpGaD
Ergotamine—HTR1E—Signaling by GPCR—EGFR—adrenal gland cancer	5.17e-05	0.000378	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—MEN1—adrenal gland cancer	5.15e-05	0.000376	CbGpPWpGaD
Ergotamine—HTR1A—GPCR downstream signaling—POMC—adrenal gland cancer	5.09e-05	0.000372	CbGpPWpGaD
Ergotamine—HTR2C—GPCR downstream signaling—POMC—adrenal gland cancer	5.06e-05	0.00037	CbGpPWpGaD
Ergotamine—HTR2B—Signaling Pathways—IGF2—adrenal gland cancer	5.04e-05	0.000369	CbGpPWpGaD
Ergotamine—HTR1A—Signaling Pathways—PRKACA—adrenal gland cancer	5e-05	0.000366	CbGpPWpGaD
Ergotamine—HTR2B—Signaling Pathways—GNAS—adrenal gland cancer	5e-05	0.000365	CbGpPWpGaD
Ergotamine—HTR2C—Signaling Pathways—PRKACA—adrenal gland cancer	4.98e-05	0.000364	CbGpPWpGaD
Ergotamine—HTR2B—Signaling Pathways—IGF1R—adrenal gland cancer	4.88e-05	0.000356	CbGpPWpGaD
Ergotamine—ADRA1D—Signaling Pathways—CDC42—adrenal gland cancer	4.87e-05	0.000356	CbGpPWpGaD
Ergotamine—ADRA1B—GPCR downstream signaling—POMC—adrenal gland cancer	4.85e-05	0.000354	CbGpPWpGaD
Ergotamine—ADRA2B—Signaling by GPCR—POMC—adrenal gland cancer	4.79e-05	0.00035	CbGpPWpGaD
Ergotamine—CYP1A2—Metabolism—RRM1—adrenal gland cancer	4.77e-05	0.000349	CbGpPWpGaD
Ergotamine—CYP1A2—Metabolism—SDHD—adrenal gland cancer	4.77e-05	0.000349	CbGpPWpGaD
Ergotamine—ADRA1B—Signaling Pathways—PRKACA—adrenal gland cancer	4.77e-05	0.000348	CbGpPWpGaD
Ergotamine—ADRA2A—Metabolism—PRKACA—adrenal gland cancer	4.7e-05	0.000344	CbGpPWpGaD
Ergotamine—ADRA1D—Signaling Pathways—IGF2—adrenal gland cancer	4.69e-05	0.000343	CbGpPWpGaD
Ergotamine—ADRA1D—Signaling Pathways—GNAS—adrenal gland cancer	4.65e-05	0.00034	CbGpPWpGaD
Ergotamine—HTR1A—Signaling by GPCR—POMC—adrenal gland cancer	4.62e-05	0.000338	CbGpPWpGaD
Ergotamine—HTR2C—Signaling by GPCR—POMC—adrenal gland cancer	4.6e-05	0.000336	CbGpPWpGaD
Ergotamine—HTR1D—Signaling Pathways—TERT—adrenal gland cancer	4.56e-05	0.000333	CbGpPWpGaD
Ergotamine—ADRA1D—Signaling Pathways—IGF1R—adrenal gland cancer	4.54e-05	0.000332	CbGpPWpGaD
Ergotamine—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—adrenal gland cancer	4.53e-05	0.000331	CbGpPWpGaD
Ergotamine—HTR1B—Signaling Pathways—TERT—adrenal gland cancer	4.47e-05	0.000327	CbGpPWpGaD
Ergotamine—DRD2—GPCR downstream signaling—POMC—adrenal gland cancer	4.47e-05	0.000326	CbGpPWpGaD
Ergotamine—ABCB1—Metabolism—MED12—adrenal gland cancer	4.46e-05	0.000326	CbGpPWpGaD
Ergotamine—ADRA1B—Signaling by GPCR—POMC—adrenal gland cancer	4.4e-05	0.000322	CbGpPWpGaD
Ergotamine—HTR2A—GPCR downstream signaling—POMC—adrenal gland cancer	4.4e-05	0.000321	CbGpPWpGaD
Ergotamine—ADRA2B—Signaling Pathways—CDC42—adrenal gland cancer	4.4e-05	0.000321	CbGpPWpGaD
Ergotamine—DRD2—Signaling Pathways—PRKACA—adrenal gland cancer	4.39e-05	0.000321	CbGpPWpGaD
Ergotamine—HTR2A—Signaling Pathways—PRKACA—adrenal gland cancer	4.32e-05	0.000316	CbGpPWpGaD
Ergotamine—ADRA1A—GPCR downstream signaling—POMC—adrenal gland cancer	4.31e-05	0.000315	CbGpPWpGaD
Ergotamine—HTR1A—Signaling Pathways—CDC42—adrenal gland cancer	4.24e-05	0.00031	CbGpPWpGaD
Ergotamine—ADRA2B—Signaling Pathways—IGF2—adrenal gland cancer	4.24e-05	0.00031	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling Pathways—PRKACA—adrenal gland cancer	4.23e-05	0.000309	CbGpPWpGaD
Ergotamine—HTR2C—Signaling Pathways—CDC42—adrenal gland cancer	4.22e-05	0.000308	CbGpPWpGaD
Ergotamine—ADRA2B—Signaling Pathways—GNAS—adrenal gland cancer	4.2e-05	0.000307	CbGpPWpGaD
Ergotamine—HTR2B—Signaling Pathways—TERT—adrenal gland cancer	4.2e-05	0.000307	CbGpPWpGaD
Ergotamine—ADRA2B—Signaling Pathways—IGF1R—adrenal gland cancer	4.1e-05	0.000299	CbGpPWpGaD
Ergotamine—HTR1A—Signaling Pathways—IGF2—adrenal gland cancer	4.09e-05	0.000299	CbGpPWpGaD
Ergotamine—HTR1F—Signaling Pathways—CTNNB1—adrenal gland cancer	4.09e-05	0.000298	CbGpPWpGaD
Ergotamine—HTR2C—Signaling Pathways—IGF2—adrenal gland cancer	4.07e-05	0.000297	CbGpPWpGaD
Ergotamine—DRD2—Signaling by GPCR—POMC—adrenal gland cancer	4.06e-05	0.000296	CbGpPWpGaD
Ergotamine—HTR1A—Signaling Pathways—GNAS—adrenal gland cancer	4.06e-05	0.000296	CbGpPWpGaD
Ergotamine—ADRA1B—Signaling Pathways—CDC42—adrenal gland cancer	4.04e-05	0.000295	CbGpPWpGaD
Ergotamine—HTR2C—Signaling Pathways—GNAS—adrenal gland cancer	4.03e-05	0.000295	CbGpPWpGaD
Ergotamine—ADRA2A—GPCR downstream signaling—POMC—adrenal gland cancer	4e-05	0.000292	CbGpPWpGaD
Ergotamine—HTR2A—Signaling by GPCR—POMC—adrenal gland cancer	3.99e-05	0.000292	CbGpPWpGaD
Ergotamine—HTR1D—Signaling Pathways—BAD—adrenal gland cancer	3.97e-05	0.00029	CbGpPWpGaD
Ergotamine—ADRA2B—Hemostasis—TP53—adrenal gland cancer	3.96e-05	0.000289	CbGpPWpGaD
Ergotamine—HTR1A—Signaling Pathways—IGF1R—adrenal gland cancer	3.96e-05	0.000289	CbGpPWpGaD
Ergotamine—HTR2C—Signaling Pathways—IGF1R—adrenal gland cancer	3.94e-05	0.000287	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—PRKACA—adrenal gland cancer	3.93e-05	0.000287	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling by GPCR—POMC—adrenal gland cancer	3.91e-05	0.000286	CbGpPWpGaD
Ergotamine—ADRA1D—Signaling Pathways—TERT—adrenal gland cancer	3.91e-05	0.000285	CbGpPWpGaD
Ergotamine—ADRA1B—Signaling Pathways—IGF2—adrenal gland cancer	3.9e-05	0.000285	CbGpPWpGaD
Ergotamine—HTR1B—Signaling Pathways—BAD—adrenal gland cancer	3.89e-05	0.000284	CbGpPWpGaD
Ergotamine—ADRA1B—Signaling Pathways—GNAS—adrenal gland cancer	3.86e-05	0.000282	CbGpPWpGaD
Ergotamine—HTR1E—Signaling Pathways—CTNNB1—adrenal gland cancer	3.85e-05	0.000282	CbGpPWpGaD
Ergotamine—ADRA2A—Metabolism—GNAS—adrenal gland cancer	3.81e-05	0.000278	CbGpPWpGaD
Ergotamine—ADRA1B—Signaling Pathways—IGF1R—adrenal gland cancer	3.77e-05	0.000275	CbGpPWpGaD
Ergotamine—ADRA2A—Metabolism—ABCB1—adrenal gland cancer	3.74e-05	0.000273	CbGpPWpGaD
Ergotamine—DRD2—Signaling Pathways—CDC42—adrenal gland cancer	3.73e-05	0.000272	CbGpPWpGaD
Ergotamine—CYP3A4—Metabolism—SDHD—adrenal gland cancer	3.68e-05	0.000269	CbGpPWpGaD
Ergotamine—CYP3A4—Metabolism—RRM1—adrenal gland cancer	3.68e-05	0.000269	CbGpPWpGaD
Ergotamine—HTR2A—Signaling Pathways—CDC42—adrenal gland cancer	3.67e-05	0.000268	CbGpPWpGaD
Ergotamine—HTR1D—Signaling Pathways—POMC—adrenal gland cancer	3.66e-05	0.000267	CbGpPWpGaD
Ergotamine—HTR2B—Signaling Pathways—BAD—adrenal gland cancer	3.65e-05	0.000267	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling by GPCR—POMC—adrenal gland cancer	3.63e-05	0.000265	CbGpPWpGaD
Ergotamine—HTR1D—Signaling Pathways—BRAF—adrenal gland cancer	3.62e-05	0.000264	CbGpPWpGaD
Ergotamine—DRD2—Signaling Pathways—IGF2—adrenal gland cancer	3.59e-05	0.000262	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling Pathways—CDC42—adrenal gland cancer	3.59e-05	0.000262	CbGpPWpGaD
Ergotamine—HTR1B—Signaling Pathways—POMC—adrenal gland cancer	3.58e-05	0.000262	CbGpPWpGaD
Ergotamine—DRD2—Signaling Pathways—GNAS—adrenal gland cancer	3.56e-05	0.00026	CbGpPWpGaD
Ergotamine—CYP1A2—Metabolism—MED12—adrenal gland cancer	3.56e-05	0.00026	CbGpPWpGaD
Ergotamine—HTR1B—Signaling Pathways—BRAF—adrenal gland cancer	3.54e-05	0.000259	CbGpPWpGaD
Ergotamine—HTR2A—Signaling Pathways—IGF2—adrenal gland cancer	3.53e-05	0.000258	CbGpPWpGaD
Ergotamine—ADRA2B—Signaling Pathways—TERT—adrenal gland cancer	3.53e-05	0.000258	CbGpPWpGaD
Ergotamine—HTR1D—Signaling by GPCR—EGFR—adrenal gland cancer	3.5e-05	0.000256	CbGpPWpGaD
Ergotamine—HTR2A—Signaling Pathways—GNAS—adrenal gland cancer	3.5e-05	0.000256	CbGpPWpGaD
Ergotamine—DRD2—Signaling Pathways—IGF1R—adrenal gland cancer	3.47e-05	0.000254	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling Pathways—IGF2—adrenal gland cancer	3.46e-05	0.000253	CbGpPWpGaD
Ergotamine—HTR1B—Signaling by GPCR—EGFR—adrenal gland cancer	3.43e-05	0.000251	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling Pathways—GNAS—adrenal gland cancer	3.43e-05	0.000251	CbGpPWpGaD
Ergotamine—HTR2A—Signaling Pathways—IGF1R—adrenal gland cancer	3.42e-05	0.00025	CbGpPWpGaD
Ergotamine—HTR1A—Signaling Pathways—TERT—adrenal gland cancer	3.4e-05	0.000249	CbGpPWpGaD
Ergotamine—ADRA1D—Signaling Pathways—BAD—adrenal gland cancer	3.4e-05	0.000248	CbGpPWpGaD
Ergotamine—HTR2C—Signaling Pathways—TERT—adrenal gland cancer	3.39e-05	0.000247	CbGpPWpGaD
Ergotamine—HTR2B—Signaling Pathways—POMC—adrenal gland cancer	3.37e-05	0.000246	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling Pathways—IGF1R—adrenal gland cancer	3.35e-05	0.000244	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—CDC42—adrenal gland cancer	3.34e-05	0.000244	CbGpPWpGaD
Ergotamine—HTR2B—Signaling Pathways—BRAF—adrenal gland cancer	3.33e-05	0.000243	CbGpPWpGaD
Ergotamine—ABCB1—Metabolism—PRKACA—adrenal gland cancer	3.25e-05	0.000238	CbGpPWpGaD
Ergotamine—ADRA1B—Signaling Pathways—TERT—adrenal gland cancer	3.24e-05	0.000237	CbGpPWpGaD
Ergotamine—HTR1F—Signaling Pathways—EGFR—adrenal gland cancer	3.24e-05	0.000236	CbGpPWpGaD
Ergotamine—HTR2B—Signaling by GPCR—EGFR—adrenal gland cancer	3.22e-05	0.000235	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—IGF2—adrenal gland cancer	3.22e-05	0.000235	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—GNAS—adrenal gland cancer	3.19e-05	0.000233	CbGpPWpGaD
Ergotamine—CYP1A2—Metabolism of lipids and lipoproteins—POMC—adrenal gland cancer	3.18e-05	0.000232	CbGpPWpGaD
Ergotamine—ADRA1D—Signaling Pathways—POMC—adrenal gland cancer	3.13e-05	0.000229	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—IGF1R—adrenal gland cancer	3.11e-05	0.000227	CbGpPWpGaD
Ergotamine—ADRA1D—Signaling Pathways—BRAF—adrenal gland cancer	3.09e-05	0.000226	CbGpPWpGaD
Ergotamine—ADRA2B—Signaling Pathways—BAD—adrenal gland cancer	3.07e-05	0.000224	CbGpPWpGaD
Ergotamine—HTR1E—Signaling Pathways—EGFR—adrenal gland cancer	3.05e-05	0.000223	CbGpPWpGaD
Ergotamine—ADRA2A—Hemostasis—TP53—adrenal gland cancer	3.01e-05	0.00022	CbGpPWpGaD
Ergotamine—ADRA1D—Signaling by GPCR—EGFR—adrenal gland cancer	3e-05	0.000219	CbGpPWpGaD
Ergotamine—DRD2—Signaling Pathways—TERT—adrenal gland cancer	2.99e-05	0.000218	CbGpPWpGaD
Ergotamine—HTR1A—Signaling Pathways—BAD—adrenal gland cancer	2.96e-05	0.000216	CbGpPWpGaD
Ergotamine—HTR2C—Signaling Pathways—BAD—adrenal gland cancer	2.95e-05	0.000215	CbGpPWpGaD
Ergotamine—HTR2A—Signaling Pathways—TERT—adrenal gland cancer	2.94e-05	0.000215	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling Pathways—TERT—adrenal gland cancer	2.88e-05	0.00021	CbGpPWpGaD
Ergotamine—ADRA2B—Signaling Pathways—POMC—adrenal gland cancer	2.83e-05	0.000207	CbGpPWpGaD
Ergotamine—ADRA1B—Signaling Pathways—BAD—adrenal gland cancer	2.82e-05	0.000206	CbGpPWpGaD
Ergotamine—ADRA2B—Signaling Pathways—BRAF—adrenal gland cancer	2.79e-05	0.000204	CbGpPWpGaD
Ergotamine—CYP3A4—Metabolism—MED12—adrenal gland cancer	2.75e-05	0.000201	CbGpPWpGaD
Ergotamine—HTR1A—Signaling Pathways—POMC—adrenal gland cancer	2.73e-05	0.000199	CbGpPWpGaD
Ergotamine—HTR1F—Signaling Pathways—TP53—adrenal gland cancer	2.72e-05	0.000199	CbGpPWpGaD
Ergotamine—HTR2C—Signaling Pathways—POMC—adrenal gland cancer	2.72e-05	0.000198	CbGpPWpGaD
Ergotamine—ADRA2B—Signaling by GPCR—EGFR—adrenal gland cancer	2.71e-05	0.000198	CbGpPWpGaD
Ergotamine—HTR1A—Signaling Pathways—BRAF—adrenal gland cancer	2.7e-05	0.000197	CbGpPWpGaD
Ergotamine—HTR2C—Signaling Pathways—BRAF—adrenal gland cancer	2.68e-05	0.000196	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—TERT—adrenal gland cancer	2.68e-05	0.000195	CbGpPWpGaD
Ergotamine—ABCB1—Metabolism—GNAS—adrenal gland cancer	2.64e-05	0.000193	CbGpPWpGaD
Ergotamine—HTR1A—Signaling by GPCR—EGFR—adrenal gland cancer	2.61e-05	0.000191	CbGpPWpGaD
Ergotamine—HTR1D—Signaling Pathways—CTNNB1—adrenal gland cancer	2.61e-05	0.000191	CbGpPWpGaD
Ergotamine—DRD2—Signaling Pathways—BAD—adrenal gland cancer	2.6e-05	0.00019	CbGpPWpGaD
Ergotamine—ADRA1B—Signaling Pathways—POMC—adrenal gland cancer	2.6e-05	0.00019	CbGpPWpGaD
Ergotamine—HTR2C—Signaling by GPCR—EGFR—adrenal gland cancer	2.6e-05	0.00019	CbGpPWpGaD
Ergotamine—CYP1A2—Metabolism—PRKACA—adrenal gland cancer	2.6e-05	0.00019	CbGpPWpGaD
Ergotamine—ADRA1B—Signaling Pathways—BRAF—adrenal gland cancer	2.57e-05	0.000188	CbGpPWpGaD
Ergotamine—ADRA2A—Metabolism—POMC—adrenal gland cancer	2.57e-05	0.000188	CbGpPWpGaD
Ergotamine—HTR1E—Signaling Pathways—TP53—adrenal gland cancer	2.56e-05	0.000187	CbGpPWpGaD
Ergotamine—HTR2A—Signaling Pathways—BAD—adrenal gland cancer	2.56e-05	0.000187	CbGpPWpGaD
Ergotamine—HTR1B—Signaling Pathways—CTNNB1—adrenal gland cancer	2.56e-05	0.000187	CbGpPWpGaD
Ergotamine—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—adrenal gland cancer	2.54e-05	0.000185	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling Pathways—BAD—adrenal gland cancer	2.51e-05	0.000183	CbGpPWpGaD
Ergotamine—ADRA1B—Signaling by GPCR—EGFR—adrenal gland cancer	2.49e-05	0.000182	CbGpPWpGaD
Ergotamine—HTR2B—Signaling Pathways—CTNNB1—adrenal gland cancer	2.4e-05	0.000176	CbGpPWpGaD
Ergotamine—DRD2—Signaling Pathways—POMC—adrenal gland cancer	2.4e-05	0.000175	CbGpPWpGaD
Ergotamine—DRD2—Signaling Pathways—BRAF—adrenal gland cancer	2.37e-05	0.000173	CbGpPWpGaD
Ergotamine—HTR2A—Signaling Pathways—POMC—adrenal gland cancer	2.36e-05	0.000172	CbGpPWpGaD
Ergotamine—HTR2A—Signaling Pathways—BRAF—adrenal gland cancer	2.33e-05	0.00017	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—BAD—adrenal gland cancer	2.33e-05	0.00017	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling Pathways—POMC—adrenal gland cancer	2.31e-05	0.000169	CbGpPWpGaD
Ergotamine—DRD2—Signaling by GPCR—EGFR—adrenal gland cancer	2.29e-05	0.000168	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling Pathways—BRAF—adrenal gland cancer	2.28e-05	0.000167	CbGpPWpGaD
Ergotamine—HTR2A—Signaling by GPCR—EGFR—adrenal gland cancer	2.26e-05	0.000165	CbGpPWpGaD
Ergotamine—ADRA1D—Signaling Pathways—CTNNB1—adrenal gland cancer	2.24e-05	0.000163	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling by GPCR—EGFR—adrenal gland cancer	2.21e-05	0.000162	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—POMC—adrenal gland cancer	2.15e-05	0.000157	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—BRAF—adrenal gland cancer	2.12e-05	0.000155	CbGpPWpGaD
Ergotamine—CYP1A2—Metabolism—GNAS—adrenal gland cancer	2.1e-05	0.000154	CbGpPWpGaD
Ergotamine—HTR1D—Signaling Pathways—EGFR—adrenal gland cancer	2.07e-05	0.000151	CbGpPWpGaD
Ergotamine—CYP1A2—Metabolism—ABCB1—adrenal gland cancer	2.07e-05	0.000151	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling by GPCR—EGFR—adrenal gland cancer	2.05e-05	0.00015	CbGpPWpGaD
Ergotamine—ADRA2A—Metabolism—PTGS2—adrenal gland cancer	2.05e-05	0.00015	CbGpPWpGaD
Ergotamine—HTR1B—Signaling Pathways—EGFR—adrenal gland cancer	2.03e-05	0.000148	CbGpPWpGaD
Ergotamine—ADRA2B—Signaling Pathways—CTNNB1—adrenal gland cancer	2.02e-05	0.000147	CbGpPWpGaD
Ergotamine—CYP3A4—Metabolism—PRKACA—adrenal gland cancer	2e-05	0.000146	CbGpPWpGaD
Ergotamine—HTR1A—Signaling Pathways—CTNNB1—adrenal gland cancer	1.95e-05	0.000142	CbGpPWpGaD
Ergotamine—HTR2C—Signaling Pathways—CTNNB1—adrenal gland cancer	1.94e-05	0.000142	CbGpPWpGaD
Ergotamine—HTR2B—Signaling Pathways—EGFR—adrenal gland cancer	1.9e-05	0.000139	CbGpPWpGaD
Ergotamine—ADRA1B—Signaling Pathways—CTNNB1—adrenal gland cancer	1.86e-05	0.000136	CbGpPWpGaD
Ergotamine—ABCB1—Metabolism—POMC—adrenal gland cancer	1.77e-05	0.00013	CbGpPWpGaD
Ergotamine—ADRA1D—Signaling Pathways—EGFR—adrenal gland cancer	1.77e-05	0.000129	CbGpPWpGaD
Ergotamine—HTR1D—Signaling Pathways—TP53—adrenal gland cancer	1.74e-05	0.000127	CbGpPWpGaD
Ergotamine—DRD2—Signaling Pathways—CTNNB1—adrenal gland cancer	1.71e-05	0.000125	CbGpPWpGaD
Ergotamine—HTR1B—Signaling Pathways—TP53—adrenal gland cancer	1.7e-05	0.000124	CbGpPWpGaD
Ergotamine—HTR2A—Signaling Pathways—CTNNB1—adrenal gland cancer	1.68e-05	0.000123	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling Pathways—CTNNB1—adrenal gland cancer	1.65e-05	0.00012	CbGpPWpGaD
Ergotamine—CYP3A4—Metabolism—GNAS—adrenal gland cancer	1.62e-05	0.000119	CbGpPWpGaD
Ergotamine—ADRA2B—Signaling Pathways—EGFR—adrenal gland cancer	1.6e-05	0.000117	CbGpPWpGaD
Ergotamine—HTR2B—Signaling Pathways—TP53—adrenal gland cancer	1.6e-05	0.000117	CbGpPWpGaD
Ergotamine—CYP3A4—Metabolism—ABCB1—adrenal gland cancer	1.59e-05	0.000116	CbGpPWpGaD
Ergotamine—HTR1A—Signaling Pathways—EGFR—adrenal gland cancer	1.54e-05	0.000113	CbGpPWpGaD
Ergotamine—HTR2C—Signaling Pathways—EGFR—adrenal gland cancer	1.54e-05	0.000112	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—CTNNB1—adrenal gland cancer	1.53e-05	0.000112	CbGpPWpGaD
Ergotamine—ADRA1D—Signaling Pathways—TP53—adrenal gland cancer	1.49e-05	0.000109	CbGpPWpGaD
Ergotamine—ADRA1B—Signaling Pathways—EGFR—adrenal gland cancer	1.47e-05	0.000107	CbGpPWpGaD
Ergotamine—CYP1A2—Metabolism—POMC—adrenal gland cancer	1.42e-05	0.000104	CbGpPWpGaD
Ergotamine—ABCB1—Metabolism—PTGS2—adrenal gland cancer	1.42e-05	0.000103	CbGpPWpGaD
Ergotamine—DRD2—Signaling Pathways—EGFR—adrenal gland cancer	1.36e-05	9.9e-05	CbGpPWpGaD
Ergotamine—ADRA2B—Signaling Pathways—TP53—adrenal gland cancer	1.34e-05	9.81e-05	CbGpPWpGaD
Ergotamine—HTR2A—Signaling Pathways—EGFR—adrenal gland cancer	1.33e-05	9.74e-05	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling Pathways—EGFR—adrenal gland cancer	1.31e-05	9.54e-05	CbGpPWpGaD
Ergotamine—HTR1A—Signaling Pathways—TP53—adrenal gland cancer	1.3e-05	9.47e-05	CbGpPWpGaD
Ergotamine—HTR2C—Signaling Pathways—TP53—adrenal gland cancer	1.29e-05	9.42e-05	CbGpPWpGaD
Ergotamine—ADRA1B—Signaling Pathways—TP53—adrenal gland cancer	1.23e-05	9.02e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—EGFR—adrenal gland cancer	1.21e-05	8.86e-05	CbGpPWpGaD
Ergotamine—DRD2—Signaling Pathways—TP53—adrenal gland cancer	1.14e-05	8.31e-05	CbGpPWpGaD
Ergotamine—CYP1A2—Metabolism—PTGS2—adrenal gland cancer	1.13e-05	8.26e-05	CbGpPWpGaD
Ergotamine—HTR2A—Signaling Pathways—TP53—adrenal gland cancer	1.12e-05	8.18e-05	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling Pathways—TP53—adrenal gland cancer	1.1e-05	8.01e-05	CbGpPWpGaD
Ergotamine—CYP3A4—Metabolism—POMC—adrenal gland cancer	1.09e-05	7.99e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—TP53—adrenal gland cancer	1.02e-05	7.44e-05	CbGpPWpGaD
Ergotamine—CYP3A4—Metabolism—PTGS2—adrenal gland cancer	8.72e-06	6.37e-05	CbGpPWpGaD
